Ventyx Biosciences Q4 2023 Earnings Report $2.02 +0.13 (+6.88%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Ventyx Biosciences EPS ResultsActual EPS-$0.79Consensus EPS -$0.87Beat/MissBeat by +$0.08One Year Ago EPS-$0.62Ventyx Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVentyx Biosciences Announcement DetailsQuarterQ4 2023Date2/27/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseVTYX Earnings HistoryPowered by Ventyx Biosciences Earnings HeadlinesResearch Analysts Set Expectations for VTYX FY2029 EarningsJanuary 17 at 2:40 AM | americanbankingnews.comVentyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. WainwrightJanuary 16 at 6:23 AM | markets.businessinsider.comHenry Kissinger’s warning of Trump In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have as much as 10-fold potential over the next four years…but only for those who get in now before Trump enters the Oval Office and unleashes America’s full economic might. January 18, 2025 | Porter & Company (Ad)Ventyx Biosciences (VTYX) Gets a Hold from H.C. WainwrightJanuary 16 at 6:23 AM | markets.businessinsider.comVentyx Biosciences highlights its 2025 pipeline strategyJanuary 15 at 10:57 AM | finance.yahoo.comVentyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor PortfolioJanuary 14, 2025 | globenewswire.comSee More Ventyx Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ventyx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ventyx Biosciences and other key companies, straight to your email. Email Address About Ventyx BiosciencesVentyx Biosciences (NASDAQ:VTYX), a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.View Ventyx Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
